RA
GYRE icon

Royce & Associates’s Gyre Therapeutics GYRE Stock Holding History

Royce & Associates’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-51
Closed -$166K – 1437
2013
Q4 		$166K Hold
51
– – ﹤0.01% 1319
2013
Q3 		$212K Hold
51
– – ﹤0.01% 1299
2013
Q2 		$171K Buy
+51
New +$194K ﹤0.01% 1301

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Royce & Associates's GYRE Position: Q1 2014 in Review

Royce & Associates sold out of Gyre Therapeutics (GYRE) in Q1 2014, closing a stake of 51 shares — an estimated $166K sold.

Royce & Associates first reported a position in GYRE in Q2 2013 and held it in 3 quarters. The position peaked at $212K in Q3 2013. 64 funds tracked by Wall St. Rank hold GYRE as of Q1 2014.

  • Royce & Associates reported no remaining Gyre Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Royce & Associates sold 51 Gyre Therapeutics shares in Q1 2014, an estimated $166K.
  • Royce & Associates first reported a position in Gyre Therapeutics in Q2 2013 and held it in 3 quarters.
  • Royce & Associates's Gyre Therapeutics position peaked at $212K in Q3 2013.
  • 64 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2014.

Based on Royce & Associates's 13F filing for Q1 2014, filed 12 May 2014.